NovaBay Pharmaceuticals Toekomstige groei
Future criteriumcontroles 0/6
NovaBay Pharmaceuticals is forecast to grow earnings and revenue by 70.5% and 7.7% per annum respectively while EPS is expected to grow by 130.4% per annum.
Belangrijke informatie
70.5%
Groei van de winst
130.4%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 23.7% |
Inkomstengroei | 7.7% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 30 Aug 2024 |
Recente toekomstige groei-updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 16 | -3 | N/A | 0 | 1 |
12/31/2025 | 14 | -4 | N/A | -3 | 2 |
12/31/2024 | 11 | -6 | N/A | -4 | 2 |
6/30/2024 | 14 | -17 | -3 | -3 | N/A |
3/31/2024 | 15 | -19 | -4 | -4 | N/A |
12/31/2023 | 15 | -17 | -4 | -4 | N/A |
9/30/2023 | 13 | -15 | -5 | -5 | N/A |
6/30/2023 | 13 | -19 | -6 | -6 | N/A |
3/31/2023 | 13 | -17 | -6 | -6 | N/A |
12/31/2022 | 14 | -16 | -7 | -7 | N/A |
9/30/2022 | 14 | -9 | -10 | -10 | N/A |
6/30/2022 | 13 | -5 | -10 | -10 | N/A |
3/31/2022 | 12 | -5 | -10 | -10 | N/A |
12/31/2021 | 10 | -7 | -9 | -9 | N/A |
9/30/2021 | 9 | -7 | -6 | -6 | N/A |
6/30/2021 | 8 | -8 | -6 | -6 | N/A |
3/31/2021 | 10 | -11 | -5 | -5 | N/A |
12/31/2020 | 10 | -11 | -5 | -5 | N/A |
9/30/2020 | 10 | -13 | -5 | -5 | N/A |
6/30/2020 | 9 | -10 | -5 | -5 | N/A |
3/31/2020 | 7 | -8 | -6 | -6 | N/A |
12/31/2019 | 7 | -10 | -8 | -8 | N/A |
9/30/2019 | 8 | -8 | -9 | -8 | N/A |
6/30/2019 | 10 | -10 | -9 | -9 | N/A |
3/31/2019 | 11 | -9 | -8 | -8 | N/A |
12/31/2018 | 13 | -7 | -6 | -6 | N/A |
9/30/2018 | 15 | -4 | -7 | -7 | N/A |
6/30/2018 | 16 | -5 | -5 | -5 | N/A |
3/31/2018 | 17 | -6 | N/A | -5 | N/A |
12/31/2017 | 18 | -7 | N/A | -6 | N/A |
9/30/2017 | 16 | -10 | N/A | -4 | N/A |
6/30/2017 | 15 | -11 | N/A | -8 | N/A |
3/31/2017 | 14 | -12 | N/A | -9 | N/A |
12/31/2016 | 12 | -13 | N/A | -12 | N/A |
9/30/2016 | 9 | -16 | N/A | -16 | N/A |
6/30/2016 | 7 | -17 | N/A | -16 | N/A |
3/31/2016 | 6 | -19 | N/A | -19 | N/A |
12/31/2015 | 4 | -19 | N/A | -19 | N/A |
9/30/2015 | 3 | -19 | N/A | -18 | N/A |
6/30/2015 | 2 | -18 | N/A | -17 | N/A |
3/31/2015 | 1 | -16 | N/A | -15 | N/A |
12/31/2014 | 1 | -15 | N/A | -15 | N/A |
9/30/2014 | 1 | -15 | N/A | -16 | N/A |
6/30/2014 | 2 | -14 | N/A | -15 | N/A |
3/31/2014 | 3 | -16 | N/A | -14 | N/A |
12/31/2013 | 3 | -16 | N/A | -13 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: NBY is forecast to remain unprofitable over the next 3 years.
Winst versus markt: NBY is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: NBY is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: NBY's revenue (7.7% per year) is forecast to grow slower than the US market (8.9% per year).
Hoge groei-inkomsten: NBY's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if NBY's Return on Equity is forecast to be high in 3 years time